Clinical Trials Browser

INDUSTRY × Lymphoma, B-Cell, Marginal Zone × obinutuzumab × Clear all

NCT05100862 2026-05-27

MAHOGANY

Phase 3 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05326308 2025-09-23

ARIADNE

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT05653271 2025-08-11

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Phase 1 Recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04796922 2022-07-18

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone